
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Boston - Organogenesis, which pioneered the engineered skin Apligraf, filed for Chapter 11 bankruptcy protection in September.






